.Pharmacolibrary.Drugs.ATC.J.J05AE05 .Pharmacolibrary.Drugs.ATC.J.J05AE05| name: | Amprenavir |
| ATC code: | J05AE05 | route: | oral |
| n-compartments | 2 |
Amprenavir is a protease inhibitor antiretroviral drug used for the treatment of HIV infection. It was approved for use in combination with other antiretroviral agents for the management of HIV-1 infection in adults and pediatric patients. However, amprenavir has been discontinued in many countries and replaced by more potent protease inhibitors with better pharmacokinetic profiles.
Pharmacokinetic parameters observed in healthy adult volunteers (both sexes) after single oral dose administration.
Sadler, BM, et al., & Stein, DS (2001). Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects. Journal of clinical pharmacology 41(4) 386–396. DOI:10.1177/00912700122010249 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11304895
Barbour, AM, et al., & Wire, MB (2014). Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients. Journal of clinical pharmacology 54(2) 206–214. DOI:10.1002/jcph.205 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25272370
Pal, D, & Mitra, AK (2006). MDR- and CYP3A4-mediated drug-herbal interactions. Life sciences 78(18) 2131–2145. DOI:10.1016/j.lfs.2005.12.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16442130